Skip to main content

Ampicillin dosing in premature infants for early-onset sepsis: exposure-driven efficacy, safety, and stewardship.

Publication ,  Journal Article
Le, J; Greenberg, RG; Yoo, Y; Clark, RH; Benjamin, DK; Zimmerman, KO; Cohen-Wolkowiez, M; Wade, KC ...
Published in: J Perinatol
July 2022

OBJECTIVE: Define optimal ampicillin dosing for empiric early-onset sepsis (EOS) therapy in preterm neonates. STUDY DESIGN: We simulated ampicillin concentrations in newborns (birthweight < 1500 g; gestational age 22-27 weeks), summarizing three 48 h regimens: high 100 mg/kg Q8hr, medium 100 mg/kg Q12hr, and standard 50 mg/kg Q12hr. Concentration data were analyzed for concentration above minimum inhibitory concentration (MIC), below neurotoxicity threshold (Cmax ≤ 140 mcg/mL), and duration limited to 48 h. RESULTS: Among 34,689 newborns, all dosing regimens provided concentrations above MIC through 48 h, but Cmax exceeded the neurotoxicity threshold. With the 4-dose standard regimen, >90% maintained concentrations >MIC beyond 48 h. With the 2-dose regimen, newborns maintained the mean concentration >MIC within the 48 h culture window and below neurotoxicity level. Infants 22-24 weeks' gestation had higher drug concentrations and more prolonged exposure duration than 25-27 weeks' gestation. CONCLUSIONS: For EOS in preterm infants, two ampicillin doses (50 mg/kg) provided optimal bactericidal exposures, while minimizing potential toxicity.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Perinatol

DOI

EISSN

1476-5543

Publication Date

July 2022

Volume

42

Issue

7

Start / End Page

959 / 964

Location

United States

Related Subject Headings

  • Sepsis
  • Pediatrics
  • Infant, Very Low Birth Weight
  • Infant, Premature, Diseases
  • Infant, Premature
  • Infant, Newborn
  • Infant
  • Humans
  • Anti-Bacterial Agents
  • Ampicillin
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Le, J., Greenberg, R. G., Yoo, Y., Clark, R. H., Benjamin, D. K., Zimmerman, K. O., … Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee, . (2022). Ampicillin dosing in premature infants for early-onset sepsis: exposure-driven efficacy, safety, and stewardship. J Perinatol, 42(7), 959–964. https://doi.org/10.1038/s41372-022-01344-2
Le, Jennifer, Rachel G. Greenberg, YoungJun Yoo, Reese H. Clark, Daniel K. Benjamin, Kanecia O. Zimmerman, Michael Cohen-Wolkowiez, Kelly C. Wade, and Kelly C. Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee. “Ampicillin dosing in premature infants for early-onset sepsis: exposure-driven efficacy, safety, and stewardship.J Perinatol 42, no. 7 (July 2022): 959–64. https://doi.org/10.1038/s41372-022-01344-2.
Le J, Greenberg RG, Yoo Y, Clark RH, Benjamin DK, Zimmerman KO, et al. Ampicillin dosing in premature infants for early-onset sepsis: exposure-driven efficacy, safety, and stewardship. J Perinatol. 2022 Jul;42(7):959–64.
Le, Jennifer, et al. “Ampicillin dosing in premature infants for early-onset sepsis: exposure-driven efficacy, safety, and stewardship.J Perinatol, vol. 42, no. 7, July 2022, pp. 959–64. Pubmed, doi:10.1038/s41372-022-01344-2.
Le J, Greenberg RG, Yoo Y, Clark RH, Benjamin DK, Zimmerman KO, Cohen-Wolkowiez M, Wade KC, Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee. Ampicillin dosing in premature infants for early-onset sepsis: exposure-driven efficacy, safety, and stewardship. J Perinatol. 2022 Jul;42(7):959–964.

Published In

J Perinatol

DOI

EISSN

1476-5543

Publication Date

July 2022

Volume

42

Issue

7

Start / End Page

959 / 964

Location

United States

Related Subject Headings

  • Sepsis
  • Pediatrics
  • Infant, Very Low Birth Weight
  • Infant, Premature, Diseases
  • Infant, Premature
  • Infant, Newborn
  • Infant
  • Humans
  • Anti-Bacterial Agents
  • Ampicillin